Pfizer Oncology Pipeline Takes Hit With Dacomitinib Lung Failure
This article was originally published in The Pink Sheet Daily
Expectations for the asset hadn’t been high, but failure of two Phase III lung cancer studies of the irreversible pan-HER inhibitor dacomitinib may remove a potential competitor for Boehringer Ingelheim’s recently approved irreversible EGFR inhibitor Gilotrif.
You may also be interested in...
NDA and BLA submission news from our US FDA Performance Tracker.
Pfizer’s emphasis on oncology has yielded three new drug approvals in the last 20 months and another two promising drugs on the horizon. It is a notable achievement, but investors may be wondering when the results are going to be felt on the top line.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.